Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Harmony Biosciences Holdings (HRMY) Cost of Revenue (2019 - 2025)

Historic Cost of Revenue for Harmony Biosciences Holdings (HRMY) over the last 7 years, with Q3 2025 value amounting to $59.6 million.

  • Harmony Biosciences Holdings' Cost of Revenue rose 3944.08% to $59.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $184.2 million, marking a year-over-year increase of 2655.16%. This contributed to the annual value of $156.8 million for FY2024, which is 2934.69% up from last year.
  • Latest data reveals that Harmony Biosciences Holdings reported Cost of Revenue of $59.6 million as of Q3 2025, which was up 3944.08% from $38.2 million recorded in Q2 2025.
  • Harmony Biosciences Holdings' 5-year Cost of Revenue high stood at $59.6 million for Q3 2025, and its period low was $15.5 million during Q1 2021.
  • Its 5-year average for Cost of Revenue is $29.7 million, with a median of $25.3 million in 2022.
  • Its Cost of Revenue has fluctuated over the past 5 years, first skyrocketed by 902.61% in 2021, then surged by 7075.7% in 2023.
  • Harmony Biosciences Holdings' Cost of Revenue (Quarter) stood at $19.1 million in 2021, then soared by 32.25% to $25.3 million in 2022, then soared by 70.76% to $43.2 million in 2023, then increased by 26.09% to $54.4 million in 2024, then grew by 9.63% to $59.6 million in 2025.
  • Its Cost of Revenue was $59.6 million in Q3 2025, compared to $38.2 million in Q2 2025 and $32.0 million in Q1 2025.